Subscribe to Search results

The Belfast Haemophilia annual returns for 1978 showed the use of cryoprecipitate (250,646), NHS concentrate (186,992), Hemofil (290,599) and Kryobulin (334,390).

Published on:

In 1979 the vast bulk of treatment at the Belfast Haemophilia Centre was with commercial concentrates (Hemofil: 557,655 units, Kryobulin: 440,051).

Published on:

In her statement to the Inquiry, Dr Mayne noted that she performed liver function tests on patients at Belfast Haemophilia Centre as she was apprehensive about the long term effects of IV treatment.

Published on:

In a HIV Haemophilia litigation report, Dr Mayne suggested that the risk of NANB could progress to Hepatitis was known in 1977 but the full significance of its effects was not investigated until the mid-late 1980's.

Published on:

Eric Preston in his statement to the Lindsay Tribunal noted that the haemophilia centre at Sheffield was first based at the Royal Infirmary before moving to Royal Hallamshire Hospital. It was a reference centre but not one of the larger reference centres.

Published on:

The first director of the Haemophilia Centre at Sheffield was Professor Eddie Blackburn.

Published on:

In his statement to the Lindsay Tribunal, Dr Preston believed that in 1978 it had been shown that Non A-Non B Hepatitis was a very serious disorder.

Published on:

In his statement to the Lindsay Tribunal, Dr Preston asserted that the amount of Factor VIII and Factor IX given in the Haemophilia Centre was much less than that in other centres.

Published on:

Sheffield Haemophilia Centre participated in a formal trial of an Armour heat-treated concentrate beginning in April 1984. Two patients became ill with hepatitis. Dr Preston's recollection was that they withdrew from that study and moved to a study with colleagues in other centres, using an Alpha product.

Published on:

The Sheffield haemophilia centre was a reference centre, but not one of the larger centres. At Sheffield, there was a particular focus on hepatitis and liver disease, with significant research being undertaken there.

Published on:

At the Sheffield haemophilia centre, the amount of Factor 8 and Factor 9 given to patients was very much less than other reference centres, although Dr Preston did not think this reflected a deliberate decision to take a conservative approach.

Published on:

Dr Preston told the Observer "in 1978 we showed quite definitely that non-A, non-B was a very serious disorder. The Department of Health should have responded by pushing for ways to inactivate the virus in the blood, or given patients the choice of an alternative."

Published on:

Dr Preston confirmed his views to the Inquiry that "The Department of Health should have responded by pushing for ways to inactivate the virus in the blood, or given patients the choice of an alternative."

Published on:

A survey between Sheffield and the Royal Free showed that approximately one third of the patients studied had the appearance of chronic active (aggressive) hepatitis.

Published on:

Dr Preston's policy was to treat people with mild haemophilia with DDAVP as soon as it became available.

Published on:

Dr Preston stated in his evidence to the Inquiry that whilst the hepatitis risk from commercial products was substantially greater than from NHS products, "there were insufficient NHS products for the treatment of Royal Hallamshire Hospital patients".

Published on:

Dr Preston confirmed that part of his approach to patients was to "keep individual patients on the same concentrate, and the same 'batch' for as long as possible to minimise exposure to different blood donations"

Published on:

Dr Preston does not recall telling patients that the treatment they were receiving might expose them to the risk of chronic liver disease.

Published on:

Dr preston's view was that the amount of Factor 8 (and Factor 9) given to patients was very much less than the majority of other reference centres.

Published on:

Dr Preston's approach to purchasing a number of different commercial concentrates was "not putting all the eggs in one basket in case something happened with the supply chain..." and "keep individual patients on the same concentrate, and the same 'batch' for as long as possible to minimise exposure to different blood donations."

Published on: